2010 Marketing uses many tools to inform consumers, business and others about client news and information. This week we used Business Wire for a international release on HPV.
HiFi DNA Tech Tells FDA to Reduce Unnecessary Biopsies on Women; Rescind Approval of Expanded Use of HPV Test Results for Sending Patients to Cancer Workup
The Trumbull, CT-based HiFi DNA Tech wants the US Food and Drug Administration (FDA) to reduce unnecessary biopsies on women, by rescinding its approval of expanded use of human papillomavirus (HPV) test results for triage referral to colposcopy. “More than 95% of referrals to colposcopic biopsy for diagnostic workup in the U.S. are performed needlessly on healthy women or women who have mostly reversible cervical cellular change. Screening with combined cytologic and HPV testing leads to the highest number of excessive colposcopic referrals,” quoted Sin Hang Lee, M.D. from a publication by the Dept. of Health Policy and Management, Harvard School of Public Health in his letter sent to the FDA Commissioner. For the entire release, click here.
Comments